Treats cataplexy or excessive daytime sleepiness (EDS). ANDA 210523, held by Ascent Pharmaceuticals. Sodium Oxybate.
As of Nov 21, 2026, ANDA 210523 (Sodium Oxybate), held by Ascent Pharmaceuticals, was first approved by FDA on Nov 5, 2025, with 0 approved supplements and 0 published complete response letters.
Sodium oxybate oral solution is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 5, 2025 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sodium Oxybate0.5GM/ML · solution;oral | Sodium Oxybate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters